These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25802286)

  • 1. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.
    Rhodes NJ; Gardiner BJ; Neely MN; Grayson ML; Ellis AG; Lawrentschuk N; Frauman AG; Maxwell KM; Zembower TR; Scheetz MH
    J Antimicrob Chemother; 2015 Jul; 70(7):2068-73. PubMed ID: 25802286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?
    Gardiner BJ; Mahony AA; Ellis AG; Lawrentschuk N; Bolton DM; Zeglinski PT; Frauman AG; Grayson ML
    Clin Infect Dis; 2014 Feb; 58(4):e101-5. PubMed ID: 24170195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.
    Kalalahti I; Huotari K; Lahdensuo K; Tarkka E; Santti H; Rannikko A; Pätäri-Sampo A
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1055-1060. PubMed ID: 29500572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers.
    Wijma RA; Koch BCP; van Gelder T; Mouton JW
    Clin Microbiol Infect; 2018 May; 24(5):528-532. PubMed ID: 28867662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG; Parkinson K; Higgins S; Denisuik A; Adam H; Pitout J; Noreddin A; Karlowsky JA
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fosfomycin in chickens after a single intravenous dose and tissue levels following chronic oral administration.
    Aramayona JJ; Bregante MA; Solans C; Rueda S; Fraile LJ; Garcia MA
    Vet Res; 1997; 28(6):581-8. PubMed ID: 9428152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate.
    Ongün S; Aslan G; Avkan-Oguz V
    Urol Int; 2012; 89(4):439-44. PubMed ID: 23006631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and Prostatic Tissue Concentrations of Cefazolin, Ciprofloxacin and Fosfomycin after Prophylactic Use for Transurethral Resection of the Prostate.
    Sobels A; Lentjes KJ; Froeling FMJA; van Nieuwkoop C; Wilms EB
    Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin.
    Lista F; Redondo C; Meilán E; García-Tello A; Ramón de Fata F; Angulo JC
    Actas Urol Esp; 2014; 38(6):391-6. PubMed ID: 24775812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline.
    Cunha BA; Gran A; Raza M
    Int J Antimicrob Agents; 2015 Apr; 45(4):427-9. PubMed ID: 25662814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose.
    Lugg J; Lettieri J; Stass H; Agarwal V
    J Chemother; 2008 Apr; 20(2):213-8. PubMed ID: 18467248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target site penetration of fosfomycin in critically ill patients.
    Joukhadar C; Klein N; Dittrich P; Zeitlinger M; Geppert A; Skhirtladze K; Frossard M; Heinz G; Müller M
    J Antimicrob Chemother; 2003 May; 51(5):1247-52. PubMed ID: 12668580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort.
    Carignan A; Sabbagh R; Masse V; Gagnon N; Montpetit LP; Smith MA; Raymond M; Allard C; Bergeron C; Pépin J
    J Glob Antimicrob Resist; 2019 Jun; 17():112-116. PubMed ID: 30553114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial.
    Dorn C; Petroff D; Neumann N; Kratzer A; El-Najjar N; Dietrich A; Kloft C; Zeitlinger M; Kees MG; Kees F; Wrigge H; Simon P
    J Antimicrob Chemother; 2019 Aug; 74(8):2335-2340. PubMed ID: 31086958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery.
    Moine P; Fish DN
    Int J Antimicrob Agents; 2013 Feb; 41(2):167-73. PubMed ID: 23182539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.
    Gattringer R; Meyer B; Heinz G; Guttmann C; Zeitlinger M; Joukhadar C; Dittrich P; Thalhammer F
    J Antimicrob Chemother; 2006 Aug; 58(2):367-71. PubMed ID: 16782745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Two Fosfomycin Regimens as Antimicrobial Prophylaxis for Transrectal Prostate Biopsy: A Randomised Study.
    D'Elia C; Mian C; Hanspeter E; Ladurner C; Palermo SM; Pycha S; Saleh O; Cai T; Spoladore G; Kafka M; Pycha A; Trenti E
    Urol Int; 2019; 103(4):433-438. PubMed ID: 31614361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.
    Sauermann R; Karch R; Langenberger H; Kettenbach J; Mayer-Helm B; Petsch M; Wagner C; Sautner T; Gattringer R; Karanikas G; Joukhadar C
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4448-54. PubMed ID: 16251282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.